Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 8 minute read Pharma Industry News From Phase 3 data to Wall Street panic: Why MoonLake Immunotherapeutics lost 89% overnight MoonLake’s VELA Phase 3 update rattled investors as MLTX crashed about 89%. Find out what the data really says and how week-52 could change the outlook. byPallavi MadhirajuSeptember 29, 2025